×
About 2,175 results

ALLMedicine™ Prader-Willi Center

Research & Reviews  791 results

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
https://clinicaltrials.gov/ct2/show/NCT05322096

May 13th, 2022 - RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study ...

Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Wil...
https://doi.org/10.2174/1871530322666220509225637
Endocrine, Metabolic & Immune Disorders Drug Targets; Sani E, Prato GD et. al.

May 12th, 2022 - Prader-Willi syndrome is the most frequent genetic cause of obesity and is often complicated by glucose metabolism alterations. Conventional therapies prescribed in type 2 diabetes frequently failed to achieve adequate glycemic control in patients...

Single-center real-life experience with testosterone treatment in adult men with Prader...
https://doi.org/10.1002/ajmg.a.62770
American Journal of Medical Genetics. Part A; Nolan BJ, Proietto J et. al.

May 10th, 2022 - Hypogonadism is the most frequent hormonal deficiency in individuals with Prader-Willi syndrome (PWS). This often necessitates testosterone treatment, but limited data are available to guide testosterone treatment in adult men with PWS. We aimed t...

Do patients with Prader-Willi syndrome have favorable glucose metabolism?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077846
Orphanet Journal of Rare Diseases; Qian Y, Xia F et. al.

May 8th, 2022 - In recent years, more studies have observed that patients with Prader-Willi syndrome have lower insulin levels and lower insulin resistance than body mass index-matched controls, which may suggest protected glucose metabolism. The PubMed and Web o...

see more →

Guidelines  1 results

Clinical report—health supervision for children with Prader-Willi syndrome.
https://doi.org/10.1542/peds.2010-2820
Pediatrics McCandless SE,

Dec 29th, 2010 - This set of guidelines was designed to assist the pediatrician in caring for children with Prader-Willi syndrome diagnosed by clinical features and confirmed by molecular testing. Prader-Willi syndrome provides an excellent example of how early di...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  37 results

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
https://clinicaltrials.gov/ct2/show/NCT05322096

May 13th, 2022 - RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study ...

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome
https://clinicaltrials.gov/ct2/show/NCT05198362

Apr 11th, 2022 - For the double-blind portion of the study, dosing will be initiated in a subgroup of adults who are 18-65 years of age. Following independent Data Monitoring Board review of subgroup safety data, and review and confirmation to proceed by FDA, enro...

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
https://clinicaltrials.gov/ct2/show/NCT03848481

Dec 2nd, 2021 - This clinical research trial aims to study the efficacy and safety of cannabidivarin (CBDV), a naturally occurring homolog of the phytocannabinoid cannabidiol (CBD) in children and young adults with Prader-Willi Syndrome (PWS). CBDV has effects in...

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
https://clinicaltrials.gov/ct2/show/NCT03649477

Nov 17th, 2021 - This is a Phase 3 randomized, double-blind study with an 8-week, placebo-controlled period designed to test the effectiveness, safety, and tolerability of LV-101 in participants with PWS. Effectiveness will be measured using both caregiver-reporte...

Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT05032326

Sep 28th, 2021 - This study is a prospective, multicentre, interventional cohort study in children with PWS over 4 years (no treatment administered). The duration of the preceding OTTB3 study is 26 weeks. An untreated cohort of children with PWS will be included a...

see more →

News  33 results

Antidepressant Transparency; Intranasal Carbetocin Not OK'd; 2021: Year of Anxiety
https://www.medpagetoday.com/psychiatry/generalpsychiatry/96750

Jan 19th, 2022 - While reporting bias persists, developers of new antidepressants have increasingly disclosed negative clinical trial outcomes. "Positive trials have always been reliably published, but negative trials, while common, have long been swept under the ...

More Metformin Recalls; Medicare Coverage for CGMs; High-Altitude Woes in T1D
https://www.medpagetoday.com/endocrinology/generalendocrinology/96457

Jan 2nd, 2022 - In the seemingly never-ending saga of metformin recalls, the FDA announced that Viona Pharmaceuticals voluntarily recalled 33 lots of metformin hydrochloride extended-release tablets 750 mg for NDMA impurity. Middle-age and older men with lower to...

Prader-Willi Syndrome: New Target for Hunger Suppression?
https://www.medscape.com/viewarticle/963259

Nov 18th, 2021 - Signaling pathways in the cerebellum, rather than the hypothalamus, could provide a key for developing new therapies for the genetic disorder. What to know: Disordered signaling in the cerebellum may help explain the insatiable appetite experience...

FDA Panel Shows Little Love for Prader-Willi Drug Candidate
https://www.medpagetoday.com/endocrinology/generalendocrinology/95477

Nov 5th, 2021 - An investigational carbetocin nasal spray for treating extreme hunger and other symptoms of Prader-Willi syndrome (PWS), a rare genetic disorder, received a near-unanimous thumbs-down from FDA advisors on Thursday. In a 12-1 vote, the agency's Psy...

Prader-Willi Syndrome Drug Receives a Resounding 'No' from FDA Advisory Panel
https://www.medscape.com/viewarticle/962380

Nov 5th, 2021 - A US Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against a new drug application (NDA) for intranasal carbetocin (Levo Therapeutics Inc.), intended to treat symptoms associated with Prader-Willi Syndrome (PWS). In a 1...

see more →

Patient Education  4 results see all →